Nanoplasmonic sensors for detecting circulating cancer biomarkers

Adv Drug Deliv Rev. 2018 Feb 1:125:48-77. doi: 10.1016/j.addr.2017.12.004. Epub 2017 Dec 14.

Abstract

The detection of cancer biomarkers represents an important aspect of cancer diagnosis and prognosis. Recently, the concept of liquid biopsy has been introduced whereby diagnosis and prognosis are performed by means of analyzing biological fluids obtained from patients to detect and quantify circulating cancer biomarkers. Unlike conventional biopsy whereby primary tumor cells are analyzed, liquid biopsy enables the detection of a wide variety of circulating cancer biomarkers, including microRNA (miRNA), circulating tumor DNA (ctDNA), proteins, exosomes and circulating tumor cells (CTCs). Among the various techniques that have been developed to detect circulating cancer biomarkers, nanoplasmonic sensors represent a promising measurement approach due to high sensitivity and specificity as well as ease of instrumentation and operation. In this review, we discuss the relevance and applicability of three different categories of nanoplasmonic sensing techniques, namely surface plasmon resonance (SPR), localized surface plasmon resonance (LSPR) and surface-enhanced Raman scattering (SERS), for the detection of different classes of circulating cancer biomarkers.

Keywords: Circulating tumor DNA; Circulating tumor cells; Exosomes; LSPR; Nanoplasmonics; SERS; microRNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / blood*
  • Humans
  • Nanostructures / chemistry
  • Nanotechnology*
  • Neoplasms / blood*
  • Neoplasms / diagnosis
  • Neoplastic Cells, Circulating / pathology*
  • Surface Plasmon Resonance*

Substances

  • Biomarkers, Tumor